Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Avignon – page 20

263 clinical trials in Avignon, France. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Avignon at a glance
263
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

263 trials in Avignon

Open in trial search

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing MK-7684A with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Prostate cancer

Not recruiting

Study on the Effectiveness and Safety of Apalutamide and GnRH Agonist in Patients with High-Risk Prostate Cancer Undergoing Radiation Therapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

IgA nephropathy

Not recruiting

Study on the Long-term Safety and Effectiveness of Sibeprenlimab for Patients with Immunoglobulin A Nephropathy (IgAN)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sibeprenlimab
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Crohn's disease

Not recruiting

Study on Managing Moderate Postoperative Recurrence in Crohn's Disease with Infliximab for Patients After Ileocolonic Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of Pembrolizumab with Chemotherapy for High-Risk Early-Stage ER+/HER2- Breast Cancer Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Doxorubicin
  • Sponsor:Merck Sharp & Dohme LLC

Myelodysplastic syndrome

Not recruiting

Study on Venetoclax and Azacitidine for Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Adenocarcinoma gastric

Not recruiting

Study on the Effectiveness and Safety of Lenvatinib, Pembrolizumab, and Chemotherapy for Patients with Advanced or Metastatic Gastroesophageal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Merck Sharp & Dohme LLC

Bladder cancer+2

Not recruiting

Study of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Diffuse large B-cell lymphoma

Not recruiting

Study on Lenalidomide, Tafasitamab, and Rituximab for Treating Diffuse Large B-Cell Lymphoma in Patients Aged 80 and Older

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Anal squamous cell carcinoma

Not recruiting

Study Comparing Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil to Standard Treatment for Patients with Advanced Anal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Fondation Franc.Cancerologie Digestive

Breast cancer+2

Not recruiting

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Hormone receptor positive breast cancer+1

Not recruiting

Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Avignon

What the registry says about research in the country

01 Oncology - Solid Tumors

Innovative research focusing on head and neck cancers, gastric cancer, and pancreatic adenocarcinoma. Studies evaluate novel combination therapies and targeted treatments to improve patient outcomes.

  • Advanced treatment strategies for HER2-positive cancers
  • EGFR-targeted therapies
  • Immunotherapy combinations

Multiple trials investigating breakthrough treatments for locally advanced and metastatic diseases.

02 Hematologic Malignancies

Groundbreaking research in multiple myeloma and lymphoma treatments, exploring novel therapeutic approaches and combination strategies.

  • Targeted antibody therapies
  • Maintenance treatment optimization
  • Novel drug combinations

Focus on improving treatment outcomes for both newly diagnosed and relapsed patients.

03 Lung Cancer Research

Comprehensive studies of non-small cell lung cancer treatments, investigating immunotherapy combinations and personalized treatment approaches.

  • Second-line therapy optimization
  • Elderly patient-specific protocols
  • Chemoimmunotherapy strategies

Emphasis on developing more effective and tolerable treatment regimens.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.